AQST

Vorhandelsmarkt: 2.85 -0.02 -0.70%

Aquestive Therapeutics Inc (AQST)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Aquestive Therapeutics Inc Stock (AQST) Company Profile

Aquestive Therapeutics Inc

Healthcare (1155)

908-941-1900

30 TECHNOLOGY DRIVE, WARREN, NJ

Nächster Verdiensttermin

Neueste SEC-Einreichungen

AQST's Discussions on Twitter

Vergleichen Sie AQST mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AQST Aquestive Therapeutics Inc	2.87	255.09M	58.36M	-25.72M	-24.91M	-0.3641
ZTS Zoetis Inc	153.47	65.50B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.03	46.99B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.18	45.96B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	14.87	17.04B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	291.38	12.77B	2.76B	1.11B	898.10M	22.77

Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-17	Eingeleitet	Cantor Fitzgerald	Overweight
2024-05-10	Eingeleitet	Leerink Partners	Outperform
2024-04-11	Eingeleitet	Piper Sandler	Overweight
2024-03-28	Eingeleitet	Raymond James	Outperform
2021-04-07	Fortgesetzt	RBC Capital Mkts	Outperform
2019-04-22	Eingeleitet	H.C. Wainwright	Buy
2019-01-03	Eingeleitet	Lake Street	Buy
2018-08-20	Eingeleitet	JMP Securities	Mkt Outperform
2018-08-20	Eingeleitet	RBC Capital Mkts	Outperform

Alle ansehen

Aquestive Therapeutics Inc Aktie (AQST) Neueste Nachrichten

Finanzdaten der Aquestive Therapeutics Inc-Aktie (AQST)

Aquestive Therapeutics Inc (AQST)

Aquestive Therapeutics Inc Stock (AQST) Company Profile

Vergleichen Sie AQST mit anderen Aktien

Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades

Aquestive Therapeutics Inc Aktie (AQST) Neueste Nachrichten

The 14% return this week takes Aquestive Therapeutics' (NASDAQ:AQST) shareholders three-year gains to 105% - simplywall.st

Geode Capital Management LLC Trims Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Russell Investments Group Ltd. Has $386,000 Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Check out these key findings about Aquestive Therapeutics Inc (AQST) - Sete News

Is Aquestive Therapeutics Inc (AQST) worth investing in despite its overvalued state? - uspostnews.com

Recent Insider Activity Suggests Potential Gains for Aquestive Therapeutics Inc (AQST) - knoxdaily.com

Investor’s Delight: Aquestive Therapeutics Inc (AQST) Closes Strong at 2.58, Up 2.79 - DWinneX

Does Aquestive Therapeutics Inc (NASDAQ: AQST) Still Need To Convince Analysts? - Stocksregister

Vanguard Group Inc. Grows Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Wellington Management Group LLP Has $639,000 Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength? - Yahoo Finance

Raymond James Financial Inc. Makes New Investment in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat

Aquestive completes marketing application for Anaphylm in U.S. - MSN

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium - The Manila Times

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium - GlobeNewswire Inc.

Raymond James Financial Inc. Invests $498,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

What is HC Wainwright’s Estimate for AQST Q1 Earnings? - Defense World

HC Wainwright Reaffirms “Buy” Rating for Aquestive Therapeutics (NASDAQ:AQST) - Defense World

New Jersey Pharma Co. Shares Positive Pediatric Study - streetwisereports.com

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by HighTower Advisors LLC - Defense World

Aquestive’s Anaphylm shows promise in pediatric study By Investing.com - Investing.com South Africa

Aquestive’s Anaphylm shows promise in pediatric study - Investing.com India

Aquestive stock gains as Anaphylm NDA completes (AQST:NASDAQ) - Seeking Alpha

Aquestive Therapeutics Concludes FDA Application For Allergy Drug With Encouraging Pediatric Trial Data - Benzinga

Aquestive Therapeutics’ Anaphylm NDA Submission and Strong Clinical Profile Support Buy Rating - TipRanks

Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film - BioSpace

Aquestive Therapeutics Awaits FDA Decision on Anaphylm NDA - TipRanks

Aquestive Therapeutics Announces Positive Topline PK Results From Its Pediatric Study And Completes The NDA Submission For Anaphylm™ (Epinephrine) Sublingual Film - MENAFN.com

Charles Schwab Investment Management Inc. Grows Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of “Buy” from Analysts - Defense World

Aquestive stock falls amid Libervant approval, Anaphylm update - MSN

Bank of New York Mellon Corp Reduces Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy - Seeking Alpha

Aquestive Therapeutics: Not For Me, But Attractive (NASDAQ:AQST) - Seeking Alpha

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) P/S Is On The Mark - simplywall.st

What is HC Wainwright’s Forecast for AQST FY2026 Earnings? - Defense World

Aquestive Therapeutics (NASDAQ:AQST) Given Buy Rating at HC Wainwright - Defense World

Aquestive Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks

Aquestive Therapeutics Advances Product Pipeline and Market Access - TipRanks

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2024 Earnings Call Transcript - Insider Monkey

Buy Rating on Aquestive Therapeutics Driven by Anaphylm’s Regulatory Progress and Strategic Launch Preparations - TipRanks

Finanzdaten der Aquestive Therapeutics Inc-Aktie (AQST)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie AQST